Although degradable scaffolds are disappointing in cardiovascular disease, researchers believe that degradable stents may change the treatment of atherosclerotic diseases of the lower extremities. The five-year follow-up results of ABSORB BTK and the one-year follow-up results of DISAPEAR show a high percentage of target blood vessel revascularization-free.
Although degradable scaffolds are di...
Although degradable scaffolds are disappointing in cardiovascular disease, researchers believe that degradable stents may change the treatment of atherosclerotic diseases of the lower extremities. The...
Experts say that although large-scale randomized controlled clinical trials of Absorb degradable scaffolds have not been successful, it does not mean that BVS is dead or that companies in the industry should postpone future research. But experts also reminded that the way forward for BVS is full of challenges.
Experts say that although large-scal...
Experts say that although large-scale randomized controlled clinical trials of Absorb degradable scaffolds have not been successful, it does not mean that BVS is dead or that companies in the industry...
70 micron total thickness, the world's only iron-based bioresorbable technology path.
2.Excellent operation performance
The scaffold is compatible with 5F catheter. The nominal diameter of post-expansion limit is +0.75mm. 3.Good visibility Two sets of gold radiopaque markers are located at both ends of scaffold to enhance the visibility.
4.Rapid endothelialization
Animal experiments show faster than mainstream permanent stents
5.Reasonable degradation profile Effective support for 6 months and complete degradation in about 1.5 years.
Product Features
1.Bioresorbable scaffold with minimum profile diameter
The scaffold is compatible with 4 ~ 6F sheath and is applicable to fine infant blood vessels of newborn.
2.High post-expansion limit
The post-expansion limit at the time of implantation is nominal diameter +1mm.
3.Secondary intervention expansion
The breakpoint design of multiple through-holes is preset on the struts of the scaffold to ensure the circumferential deconstruction as soon as possible after 6 months, which is conducive to secondary intervention expansion when necessary, and does not restrict the short-term growth of blood vessels.
4.Reasonable degradation profile
Effective support for 6 months and complete degradation in about 2 years, without restricting long-term growth of blood vessels.
Product Features
1.Thinnest
The world's thinnest scaffold with 70 μm , the world's only iron-based bioresorbable technology path.
2.Longest
The breakthrough 118mm length, can cover the lesion length up to 200mm by overlapping use which can meet the real world clinical application needs.
3.Excellent operation performance
The scaffold is compatible with 5F catheter and has excellent visibility. The nominal diameter of the post expansion limit is +0.75mm.
4.High drug utilization
The content of sirolimus is 1.4μg/mm2, with most of the drug being located on abluminal surface of the struts.
5.Reasonable degradation profile
Effective support for 6 months and fully degradable in about 1.5 years, allowing secondary intervention expansion when necessary.
